TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21789385

Group type: EXPERIMENTAL
Intervention: Remifentanil at 1.5 ng/mL (group I)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Remifentanil at 2 ng/mL (group II)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Remifentanil at 2.5 ng/mL (group III)
Number of subjects: 69
Study: 19855343

Group type: EXPERIMENTAL
Intervention: Plyometric training (PT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Habitual training (HT)
Number of subjects: 22
Study: 16954359

Group type: EXPERIMENTAL
Intervention: Low-polyphenol olive oil (2.7 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Medium-polyphenol olive oil (164 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-polyphenol olive oil (366 mg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All olive oils
Number of subjects: 200
Study: 19667682

Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 6922

Group type: COMPARATOR
Intervention: No educational brochure (Control)
Number of subjects: 6922
Study: 11361046

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) oxycodone q12h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immediate-release (IR) oxycodone qid
Number of subjects: 30
Study: 9429915

Group type: EXPERIMENTAL
Intervention: Binge Eating Scale (BES)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Questionnaire on Eating and Weight Patterns (QEWP)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Binge Eating Scale (BES) and Questionnaire on Eating and Weight Patterns (QEWP)
Number of subjects: 128
Study: 8051319

Group type: EXPERIMENTAL
Intervention: Silver nitrate stick
Number of subjects: 70

Group type: COMPARATOR
Intervention: Black ink (Control)
Number of subjects: 70
Study: 3132225

Group type: EXPERIMENTAL
Intervention: Cytology screening
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cytology and colposcopy screening
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Smaller lesions not detected by cytology screening
Number of subjects: 200
Study: 31739213

Group type: EXPERIMENTAL
Intervention: Foot reflexology (8-min for each foot, total 16 min)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine post-angiography care services (Control)
Number of subjects: 120
Study: 29931358

Group type: EXPERIMENTAL
Intervention: 60 μg (2400 IU)/d of D3
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 20 μg/d of 25(OH)D3
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both D3 and 25(OH)D3 groups combined
Number of subjects: 35
Study: 28835238

Group type: EXPERIMENTAL
Intervention: STarT Back Tool (STarT) questionnaire
Number of subjects: 475

Group type: COMPARATOR
Intervention: High-risk group
Number of subjects: 475
Study: 26338971

Group type: EXPERIMENTAL
Intervention: Vorapaxar with planned thienopyridine
Number of subjects: 16449

Group type: EXPERIMENTAL
Intervention: Vorapaxar without planned thienopyridine
Number of subjects: 16449
Study: 23154532

Group type: EXPERIMENTAL
Intervention: Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Normal saline based on insulin intensive therapy
Number of subjects: 29
Study: 21601549

Group type: EXPERIMENTAL
Intervention: Tunnelled internal jugular vein catheters (TIJC) with taurolidine lock
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF) failure patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arteriovenous fistula (AVF) success patients
Number of subjects: 0
Study: 17383202

Group type: EXPERIMENTAL
Intervention: Exclusion instructions with reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusion instructions with noise added to sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusion instructions with shortened training
Number of subjects: 0
Study: 12814155

Group type: EXPERIMENTAL
Intervention: Shuttle walk test (SWT) on a conventional corridor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Shuttle walk test (SWT) on a programmable treadmill
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Treadmill equivalent SWT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline PaO2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DLCO
Number of subjects: 20
Study: 10223232

Group type: EXPERIMENTAL
Intervention: Asian patients with HCC
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-Asian patients with HCC
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients with resectable tumors
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Patients with alpha-fetoprotein level <10 ng/mL
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Younger age at diagnosis
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Asian race
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tumor resectability and non-Asian race
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Controlling for multiple variables
Number of subjects: 76
Study: 8566739

Group type: EXPERIMENTAL
Intervention: Imidazole salicylate (IS)
Number of subjects: 67
Study: 2360836

Group type: EXPERIMENTAL
Intervention: Q-switched ruby laser pulses (694 nm, 40 to 80 nanoseconds) at a fluence of 1.5 to 8.0 J/cm2
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Q-switched ruby laser pulses (694 nm, 40 to 80 nanoseconds)
Number of subjects: 57
Study: 227433

Group type: EXPERIMENTAL
Intervention: HOE 36‐984 (nomifensine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29742746

Group type: EXPERIMENTAL
Intervention: Self-selected high-intensity interval exercise (HIIESS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Imposed high-intensity interval exercise (HIIEIMP)
Number of subjects: 14
Study: 28698075

Group type: EXPERIMENTAL
Intervention: Metformin (1500mg/day) with Clomiphene citrate (100mg/day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) (1800mg/day) with Clomiphene citrate (100mg/day)
Number of subjects: 108

Group type: COMPARATOR
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 108
Study: 25573882

Group type: EXPERIMENTAL
Intervention: Upper-tertile ACR group
Number of subjects: 445
Study: 23657509

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with exercises
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (orientation program)
Number of subjects: 100
Study: 20727236

Group type: EXPERIMENTAL
Intervention: Juice Plus+® (dietary supplement from fruits and vegetables)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 19165198

Group type: COMPARATOR
Intervention: Standard AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 3 weeks)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Accelerated AC (doxorubicin 60 mg m(‐2) + cyclophosphamide 600 mg m(‐2) every 2 weeks with pegfilgrastim)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Combined standard and accelerated AC
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combined EC (epirubicin 90 mg m(‐2) every 3 weeks or every 2 weeks with pegfilgrastim)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Accelerated AC and EC with pegfilgrastim
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Accelerated treatment
Number of subjects: 126
Study: 17956455

Group type: COMPARATOR
Intervention: Sulodexide given over 26 weeks in the Microalbuminuria Trial
Number of subjects: 3240

Group type: COMPARATOR
Intervention: Sulodexide in the Overt Nephropathy Trial
Number of subjects: 3240
Study: 14505238

Group type: EXPERIMENTAL
Intervention: 1 g of parenteral Cefazolin preoperatively
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 11704087

Group type: EXPERIMENTAL
Intervention: Multiload Cu-375 SL IUD
Number of subjects: 1013
Study: 9022487

Group type: EXPERIMENTAL
Intervention: Low dose aspirin and heparin (5000 U of unfractionated heparin subcutaneously 12 hourly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low dose aspirin (75 mg daily)
Number of subjects: 90
Study: 7939147

Group type: EXPERIMENTAL
Intervention: Conventional views (Caldwell's and Waters' views)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronal CT scans
Number of subjects: 0
Study: 29926217

Group type: EXPERIMENTAL
Intervention: Test lenalidomide capsule (25 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Revlimid® capsule (25 mg)
Number of subjects: 48
Study: 27262965

Group type: EXPERIMENTAL
Intervention: Web-based combined alcohol use and sexual assault risk reduction intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Alcohol-only intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sexual assault-only intervention
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Web-based combined intervention
Number of subjects: 264
Study: 23929423

Group type: EXPERIMENTAL
Intervention: rivaroxaban
Number of subjects: 353

Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 353
Study: 22769732

Group type: EXPERIMENTAL
Intervention: Laparo-endoscopic single-site surgery (LESS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 20540943

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no TSST)
Number of subjects: 48
Study: 19842347

Group type: EXPERIMENTAL
Intervention: Notched noise stimuli (windowed sound therapy [WST])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-notched broadband noise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noise of water
Number of subjects: 0
Study: 16784745

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 0
Study: 15468963

Group type: EXPERIMENTAL
Intervention: CsA alone (2-3 mg/kg/d)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CsA after intravenous pulse methylprednisolone therapy (CsA/PMT) (2-3 mg/kg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral prednisolone (PSL, 40-60 mg/d)
Number of subjects: 36
Study: 10946808

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemodiafiltration (CVVHDF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CRRT (both CVVH and CVVHDF)
Number of subjects: 40
Study: 9309990

Group type: EXPERIMENTAL
Intervention: Mannitol inhalation (5, 10, 20, or 40 mg to a cumulative dose of 635 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mannitol inhalation (first challenge)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mannitol inhalation (second challenge)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mannitol inhalation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Methacholine inhalation
Number of subjects: 43
Study: 8100421

Group type: EXPERIMENTAL
Intervention: 150 IU IFN-alpha A for 6 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2.5% albumin for 6 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Normal saline for 6 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 8
Study: 3105565

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31522954

Group type: EXPERIMENTAL
Intervention: Collaborative nursing care
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual nursing care
Number of subjects: 28
Study: 30786829

Group type: EXPERIMENTAL
Intervention: Vitamin K1 (10 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 27282852

Group type: EXPERIMENTAL
Intervention: Gambrosol Trio (biocompatible PD solution)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard PD solution (Dianeal)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Gambrosol Trio
Number of subjects: 101

Group type: COMPARATOR
Intervention: Gambrosol Trio and Standard PD solution
Number of subjects: 101
Study: 24323166

Group type: COMPARATOR
Intervention: Lidocaine HCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine HCl and dexamethasone sodium phosphate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine and dexamethasone sodium phosphate
Number of subjects: 60
Study: 22652561

Group type: EXPERIMENTAL
Intervention: Aggressive phototherapy (AgPT)
Number of subjects: 1974

Group type: COMPARATOR
Intervention: Conservative phototherapy
Number of subjects: 1974
Study: 20417925

Group type: EXPERIMENTAL
Intervention: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered 3 days prior to surgery (Group 1, n = 5)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subconjunctival ranibizumab (0.5 mg/0.05 mL) administered at the time of surgery (Group 2, n = 5)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study: 18605454

Group type: EXPERIMENTAL
Intervention: 0.5% fluoride varnish
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.1% fluoride varnish
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.5% sodium fluoride
Number of subjects: 150

Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 150
Study: 16003294

Group type: EXPERIMENTAL
Intervention: 80 mg/d of simvastatin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 40 mg/d of atorvastatin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12142826

Group type: EXPERIMENTAL
Intervention: Sliding compression hip screw (Dynamic Hip Screw; Synthes‐Stratec, Oberdorf, Switzerland)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intramedullary nail (Proximal Femoral Nail; Synthes‐Stratec, Oberdorf, Switzerland)
Number of subjects: 206
Study: 10350666

Group type: EXPERIMENTAL
Intervention: Hypertensive elderly patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy elderly subjects (Control)
Number of subjects: 26
Study: 7549167

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine with 2 micrograms/ml fentanyl via PCEA
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.125% bupivacaine with 2 micrograms/ml fentanyl via continuous epidural infusion (CEI)
Number of subjects: 41
Study: 1940776

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (3 g daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Acipimox (0.75 g daily)
Number of subjects: 31
Study: 6779890

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (4 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhalational powder (400 micrograms)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tablet (4 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31395485

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) at a dose of 2 mg kg‐1 IV and then IM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) at a dose of 4 mg kg‐1 IV
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 28618772

Group type: EXPERIMENTAL
Intervention: 2 mg of pitavastatin
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: 4 mg of pitavastatin
Number of subjects: 1101
Study: 26563757

Group type: EXPERIMENTAL
Intervention: Baby-Led Introduction to SolidS (BLISS) intervention with additional parent contacts (n=8) for support and education from before birth to 12 months of age.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard Well Child care provided to all parents in New Zealand (Control group).
Number of subjects: 200
Study: 22975753

Group type: EXPERIMENTAL
Intervention: CXCL13 (BCA-1)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: matrix metalloproteinase-3 (MMP-3)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: tissue inhibitor of metalloproteinases-1 (TIMP-1)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Erythrocyte sedimentation rate (ESR)
Number of subjects: 186

Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 186
Study: 21251383

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway anaesthesia combined with sacral canal block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single tracheal tube anaesthesia
Number of subjects: 60
Study: 19549331

Group type: EXPERIMENTAL
Intervention: Interim monitoring and modification of recruitment strategies
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Overall incidence of HIV
Number of subjects: 1644

Group type: EXPERIMENTAL
Intervention: Recruitment strategies based on interim analyses
Number of subjects: 1644
Study: 17462615

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg) and ambroxol HCl (30 mg) dispersible tablet (treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg roxithromycin dispersible tablet and 30 mg ambroxol HCl tablet (treatment B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 150 mg roxithromycin dispersible tablet (treatment C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 30 mg ambroxol HCl tablet (treatment D)
Number of subjects: 12
Study: 15614648

Group type: EXPERIMENTAL
Intervention: MIS group (ventral minimal invasive approach)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard group (anterolateral transgluteal approach)
Number of subjects: 50
Study: 11296098

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (150 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CCK‐4 administration
Number of subjects: 18
Study: 9247907

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with diet and exercise
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Metformin (Glucophage) with standard diet and exercise
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Troglitazone (investigational drug) with standard diet and exercise
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Trivalent chromium (not included in the program)
Number of subjects: 4000
Study: 8290882

Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum (3.6 mg, four times daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Miconazole gel (50 mg, four times daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Miconazole chewing gum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Miconazole gel
Number of subjects: 32
Study: 3326678

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 100 mg
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium 200 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Buffered aspirin 600 mg
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 31358717

Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Phosphate (ACP) containing adhesive
Number of subjects: 23

Group type: COMPARATOR
Intervention: Regular adhesive (control)
Number of subjects: 23
Study: 28387616

Group type: EXPERIMENTAL
Intervention: Prestige LP artificial disc replacement (ADR)
Number of subjects: 397

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 397
Study: 25516196

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg 3× daily via nasogastric tube for 21 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo 3× daily via nasogastric tube for 21 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22951068

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (mean dose 95.7mg, SD 48.9)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Prescribed opioids (38.8%)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Non-opioids (48.9%)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Self-management approaches (60.8%) including prayer (33.8%), vitamins (29.5%), distraction (12.7%)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Higher methadone dose
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: More medical comorbidities
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: More severe depressive symptomatology
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Urine drug screening (UDS) positive for opiates, cocaine, and amphetamines
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Self-reported substance use
Number of subjects: 489
Study: 21436459

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) dropped from optimum to suboptimum pressures for 3-5 minutes during sleep
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Physiological model of OSA
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Repeatability measurements
Number of subjects: 14
Study: 19697301

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caffeine (administered in one double-blind group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo (double-blind)
Number of subjects: 60
Study: 17898344

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for up to 14 weeks
Number of subjects: 1915
Study: 14698135

Group type: EXPERIMENTAL
Intervention: Paclitaxel (weekly or every 3 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paclitaxel (weekly)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paclitaxel (every 3 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: FAC chemotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 90
Study: 12405649

Group type: EXPERIMENTAL
Intervention: Prebiotic mixture (6 g/d of a 70% raftilose and 30% raftiline mixture)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (6 g of maltodextrin powder)
Number of subjects: 43